Subsidise artemisinin for malaria to delay resistance, say analystsBMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b2908 (Published 20 July 2009) Cite this as: BMJ 2009;339:b2908
- Bob Roehr
- 1Washington, DC
A mixture of subsidy and market forces is being touted as a way to promote the use of combination therapy for treating malaria, which the World Health Organization has recommended since 2001. The long term goal is to reduce and delay the emergence of resistance to the artemisinin family of compounds and extend their lives as effective drugs.
“If we used artemisins in the same way we used chloroquines, which was as a monotherapy, the chance that we would lose it within about 10 years is extremely high,” said Ramanan Laxminarayan, a policy analyst with the charity Resources for the Future. He was speaking at a forum in Washington, DC, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial